共 50 条
- [31] Individualized starting dose of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC): A randomized, double-blind, placebo-controlled, phase III trial (NORA)ANNALS OF ONCOLOGY, 2020, 31 : S1160 - S1161Wu, X.Zhu, J.Yin, R.Yang, J.Liu, J.Wang, J.Wu, L.Liu, Z.Gao, Y.Wang, D.Lou, G.Yang, H.Zhou, Q.Kong, B.Huang, Y.Chen, L.Li, G.An, R.Wang, K.Zhang, Y.
- [32] CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trialTrials, 19Dean A. FennellEmma KirkpatrickKelly CozensMavis NyeJason LesterGerard HannaNicola SteelePeter SzlosarekSarah DansonJoanne LordChristian OttensmeierDaniel BarnesStephanie HillMihalis KalevrasTom MaishmanGareth Griffiths
- [33] Oral nicotinamide to reduce actinic cancer: A phase 3 double-blind randomized controlled trial.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Martin, Andrew JamesChen, AndrewChoy, BonitaPenas, Pablo FernandezHalliday, GaryDalziell, RobynMcKenzie, CatrionaScolyer, Richard A.Dhillon, Haryana M.Vardy, Janette L.St George, GayaChinniah, NiraDamian, Diona
- [34] Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trialLANCET ONCOLOGY, 2015, 16 (15): : 1515 - 1524Symonds, R. PaulGourley, CharlieDavidson, SusanCarty, KarenMcCartney, ElaineRai, DebbieBanerjee, SusanaJackson, DavidLord, RosemaryMcCormack, MaryHudson, EmmaReed, NicholasFlubacher, MaxineJankowska, PetraPowell, MelanieDive, CarolineWest, Catharine M. L.Paul, James
- [35] Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2278 - 2285Gao, QingleiZhu, JianqingZhao, WeidongHuang, YiAn, RuifangZheng, HongQu, PengpengWang, LiZhou, QiWang, DanboLou, GeWang, JingWang, KeLow, JohnKong, BeihuaRozita, Abdul MalikSen, Lim ChunYin, RutieXie, XingLiu, JihongSun, WeiSu, JingyaZhang, ChunyiZang, RongyuMa, Ding
- [36] Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialLANCET ONCOLOGY, 2015, 16 (01): : 87 - 97Oza, Amit M.Cibula, DavidOaknin Benzaquen, AnaPoole, ChristopherMathijssen, Ron H. J.Sonke, Gabe S.Colombo, NicolettaSpacek, JiriVuylsteke, PeterHirte, HolgerMahner, SvenPlante, MarieSchmalfeldt, BarbaraMackay, HelenRowbottom, JacquiLowe, Elizabeth S.Dougherty, BrianBarrett, J. CarlFriedlander, Michael
- [37] Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trialLANCET ONCOLOGY, 2019, 20 (07): : 1023 - 1034Judson, IanMorden, James P.Kilburn, LucyLeahy, MichaelBenson, CharlotteBhadri, VivekCampbell-Hewson, QuentinCubedo, RicardoDangoor, AdamFox, LisaHennig, IvoJarman, KatyJoubert, WarrenKernaghan, SarahLopez Pousa, AntonioMcNeil, CatrionaSeddon, BeatriceSnowdon, ClaireTattersall, MartinToms, ChristyMartinez Trufero, JavierBliss, Judith M.
- [38] Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocolBMJ OPEN, 2021, 11 (01):Mansouri, AnitaMcGregor, NaomiDunn, RachelDobbie, SamHolmes, JaneCollins, LindaNicum, Shibani
- [39] Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trialANNALS OF ONCOLOGY, 2021, 32 (04) : 512 - 521Wu, X. H.Zhu, J. Q.Yin, R. T.Yang, J. X.Liu, J. H.Wang, J.Wu, L. Y.Liu, Z. L.Gao, Y. N.Wang, D. B.Lou, G.Yang, H. Y.Zhou, Q.Kong, B. H.Huang, Y.Chen, L. P.Li, G. L.An, R. F.Wang, K.Zhang, Y.Yan, X. J.Lu, X.Lu, W. G.Hao, M.Wang, L.Cui, H.Chen, Q. H.Abulizi, G.Huang, X. H.Tian, X. F.Wen, H.Zhang, C.Hou, J. M.Mirza, M. R.